Also trades as: BIAFW (NASDAQ) · $vol 0M
BIAF NASDAQ
bioAffinity Technologies, Inc.
1W: -9.6%
1M: -36.8%
3M: +47.8%
YTD: +39.3%
1Y: -73.2%
3Y: -96.9%
$1.66
-0.04 (-2.35%)
After Hours: $1.65 (-0.01, -0.60%)
Weekly Expected Move ±15.6%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$7.7M
52W Range0.693-15
Volume90,365
Avg Volume8,881,640
Beta-1.19
Dividend—
Analyst Ratings
Company Info
CEOMaria Zannes
Employees57
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2022-09-01
Websitebioaffinitytech.com
22211 West Interstate 10
San Antonio, TX 78257
US
San Antonio, TX 78257
US
210 698 5334
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Latest News
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung
bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M
12 Health Care Stocks Moving In Tuesday's Intraday Session
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
12 Health Care Stocks Moving In Thursday's Intraday Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rios Roberto | 0 | — | 2025-08-12 | |
| Oppenheimer John J. | 0 | — | 2025-08-12 | |
| Reveles Xavier Trini | A-Award | 21,604 | — | 2025-01-10 |
| GIRGENTI STEVEN | A-Award | 14,814 | — | 2025-01-10 |
| Zannes Maria | A-Award | 37,037 | — | 2025-01-10 |